Article ISI
ANNALS OF ONCOLOGY  (2020)

Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study

Moehler M.; Yamaguchi K.; Skoczylas T.; Campos Bragagnoli A.; Yanez P.; Tehfe M.; Poulart V.; Ajani, J. A.; Janjigian, Y. Y.